Related Experiment Video
Updated: Jul 21, 2026
08:10
The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
Debrisoquine hydroxylation in Parkinson's disease
M J Steiger1, P Lledo, N P Quinn
1Department of Clinical Neurology, St. Bartholomew's Hospital, London, England.
Acta Neurologica Scandinavica
|August 1, 1992
Summary
Young onset Parkinson's disease (YOPD) patients do not show impaired debrisoquine (DBQ) metabolism compared to controls. This suggests cytochrome P450 activity is not a primary defect in YOPD, though PD patients generally had higher DBQ metabolic ratios.
Area of Science:
- Pharmacogenetics
- Neurodegenerative Diseases
- Drug Metabolism
Background:
- Debrisoquine (DBQ) is a probe drug used to assess cytochrome P450 (CYP) enzyme activity.
- Previous studies suggested a potential link between impaired DBQ metabolism and young onset Parkinson's disease (YOPD).
- Understanding drug metabolism in Parkinson's disease (PD) is crucial for personalized treatment strategies.
Purpose of the Study:
- To investigate debrisoquine (DBQ) metabolic status in patients with Parkinson's disease (PD), specifically focusing on young onset Parkinson's disease (YOPD).
- To determine if impaired DBQ metabolism is a primary defect in YOPD.
- To explore the relationship between age of PD onset and DBQ metabolic ratio (MR).
Main Methods:
- Debrisoquine (DBQ) metabolism was assessed in 80 PD patients (26 with YOPD) and 143 controls.
- The proportion of poor metabolizers of DBQ was compared across groups.
- Correlation analysis was performed between age of disease onset and DBQ metabolic ratio (MR).
Main Results:
- No significant difference in the proportion of poor DBQ metabolizers was found between YOPD patients, other PD patients, and controls.
- There was no significant correlation between the age of PD onset and the DBQ metabolic ratio (MR).
- PD patients, irrespective of disease onset age or medication, exhibited modestly but significantly higher MR values compared to controls.
Conclusions:
- The findings do not support the hypothesis that impaired debrisoquine (DBQ) metabolism or cytochrome P450 dysfunction is a primary defect in young onset Parkinson's disease (YOPD).
- While not a primary defect in YOPD, altered DBQ metabolism (higher MR) is observed in PD patients compared to controls.
- Further research is warranted to elucidate the mechanisms behind altered drug metabolism in Parkinson's disease.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...